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Abstract
Background: The study of the interaction of a drug with plasma protein is very important because drug-protein
binding plays an important role in determination of pharmacological and toxicological properties of drugs. Our
study was designed to investigate the interaction between aceclofenac and bovine serum albumin (BSA) using
fluorescence spectroscopy at different temperatures (298 and 308 K).
Methods: Fluorescence spectroscopy was used to carry out the study. Fluorescence quenching constant was
determined from Stern-Volmer equation. Van’t Hoff equation was used to determine the thermodynamic
parameters such as free energy (ΔG), enthalpy (ΔH), and entropy (ΔS).
Results: The experimental data showed that the quenching of BSA by aceclofenac was due to a formation of a
BSA-aceclofenac complex with probable involvement of both tryptophan and tyrosine residues of BSA. Dynamic
quenching was shown for BSA by aceclofenac at the experimental conditions. The values of thermodynamic
parameters indicated that the hydrophobic forces played major roles for BSA-aceclofenac complexation. The
binding number (n) was found to be ≈1 indicating that 1 mol of BSA bound with 1 mol of aceclofenac. The
binding affinity of aceclofenac to BSA was calculated at different temperatures. It was shown that the binding
constant decreased with increasing temperatures indicating that stability of the BSA-aceclofenac complex
decreased with increasing temperatures.
Conclusions: The interaction of aceclofenac with BSA was successfully explored using a fluorescence spectroscopic
technique.
Keywords: Predictive, preventive, and personalized medicine, Aceclofenac, Bovine serum albumin, Fluorescence
spectroscopy, Drug-protein binding, Thermodynamic parameter
Background
Plasma protein binding is a very important factor in
pharmacokinetics, pharmacodynamics, and drug inter-
action. Drug-protein interaction greatly influences the ab-
sorption, distribution, metabolism, and excretion properties
of drugs [1]. A clear perception about the features of drug-
protein interaction provides insights into drug therapy and
drug design. This interaction has an effect on bioavailability
and toxicity [2–5]. In this study, bovine serum albumin
(BSA) was used as a model protein because of its low cost,
availability, and structural homology with human serum
albumin [6]. Spectral methods are a powerful tool to reveal
the binding of drugs with albumin at low concentrations.
Binding affinities can be determined by fluorescence
quenching. The fluorescence quenching technique is used
to monitor the molecular interactions because of its high
sensitivity, reproducibility, and relatively ease of use [7–10].
Aceclofenac (2-[(2,6-dichlorophenyl)amino]phenylacetoxya-
cetic acid) (Fig. 1) is a NSAID of phenyl acetic acid group
derivative possessing an anti-inflammatory property which
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is used for the treatment of osteoarthritis, rheumatoid arth-
ritis, and inflammatory disorders [11]. The cost-effective
management of diseases has been considered as an import-
ant target of drug therapy. Considering this, we aimed to
find out the possible interaction between aceclofenac and
BSA for identifying the correct binding site of aceclofenac
with the intension if any dose adjustment is required due to
interaction [12]. To optimize the use of aceclofenac as a




Aceclofenac was a kind gift from the Eskayef Bangladesh
Ltd. BSA (fatty acid free fraction V, 96–98 %) was pur-
chased from Sigma-Aldrich, USA. All other reagents used
in the study were of analytical grade and purchased from
local agents. All BSA solutions were prepared in pH 7.40
buffer solution. The buffer solution was prepared using a
mixture of disodium hydrogen phosphate (Na2HPO4) and
potassium dihydrogen phosphate (KH2PO4).
Instruments
Fluorescence measurements were performed using a
1-cm quartz cell on an FL-7000 spectrofluorophotometer
(Hitachi, Japan). For different temperatures, a thermostat
bath (Unitronic Orbital, P-Spectra, Spain) was used.
Sample preparation
Five milliliters of previously prepared 20 × 10−6 mol L−1
BSA in phosphate buffer of pH 7.4 was taken in each of
the eight test tubes. Aceclofenac was added in different
volumes to seven out of eight test tubes to have the
following concentrations: (0, 20, 40, 80, 120, 160, 240,
and 320) × 10−6 mol L−1, respectively. The ratios of ace-
clofenac and BSA ([aceclofenac]/[BSA]) in aceclofenac-
BSA system of seven test tubes were 1:1, 2:1, 4:1, 6:1,
8:1, 12:1, and 16:1, respectively.
Spectroscopic measurement
At two different temperatures (298 and 308 K), the
fluorescence emission spectra for aceclofenac-BSA sys-
tem were recorded at the two excitation wavelengths of
BSA (280 and 293 nm). The widths of both entrance
and exit slits were set to 5 nm. These emission spectra
were recorded for three times for each treatment in the
range of 320–460 nm for BSA at the same experimental
conditions since there were no emission spectra of ace-
clofenac in this range.
Results and discussion
The interaction of aceclofenac with BSA
If BSA is excited by appropriate wavelengths of light, all of
its fluorophores (tryptophan, tyrosine, and phenylalanine)
can emit fluorescence. When a 280-nm excitation wave-
length is used, the fluorescence of albumin comes from
both tryptophan and tyrosine residues, whereas a 293-nm
wavelength only excites tryptophan residue [13]. It com-
pared the fluorescence of BSA excited at 280 and 293 nm
in the presence of aceclofenac that would determine the
interactions of residues of BSA with aceclofenac. The plots
F/F0 against [aceclofenac]/[BSA] at excitation wavelengths
280 and 293 nm were compared at 298 K, respectively.
Here, F0 is the fluorescence intensity of BSA, and F is the
fluorescence intensity of BSA in presence of aceclofenac.
Figure 2 indicates that the fluorescence of BSA excited at
280 nm obviously differed from that excited at 293 nm in
the presence of aceclofenac. This difference between the
quenching of serum albumin fluorescence showed that
both tyrosine and tryptophan residues participated in the
molecular interactions between aceclofenac and BSA.
Effect of aceclofenac on the fluorescence emission
spectra of BSA
In order to determine the effect of aceclofenac on BSA,
the fluorescence emission spectra were measured at two
Fig. 1 Chemical structure of aceclofenac
Fig. 2 Fluorescence titration curve of BSA in the presence of
aceclofenac at the excitation wavelengths of 280 and 293 nm
at 298 K
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excitation wavelengths of BSA (280 and 293 nm) at 298 K.
Figure 3 shows that the fluorescence of BSA gradually de-
creases with the increasing concentration of aceclofenac,
indicating that there was a strong interaction and energy
transfer between aceclofenac and BSA at both excitation
wavelengths of BSA (λmax of BSA = 280 and 293 nm) at
298 K. As a result, there was quenching of intrinsic fluor-
escence of BSA but no significant shift of the emission
maximum wavelength was observed.
Fluorescence quenching analysis
Quenching is a process where the fluorescence intensity
of a substance decreases in the presence of a quencher
molecule [14]. The drug-protein interaction can be static
and dynamic depending on the type of interaction. A
variety of processes can result in quenching, such as
excited state reactions, energy transfer, complex forma-
tion, and collisional quenching. The formation of a com-
plex between the quencher and the fluorophore refers to
static quenching. On the other hand, collision of the
quencher and fluorophore during the excitation refers to
dynamic quenching [15]. The fluorescence quenching
data are usually analyzed by Stern-Volmer equation [16]
which is given below:
F0=F ¼ 1þ K sv Q½ 
where F0 and F are the fluorescence intensities in the ab-
sence and presence of a quencher, [Q] is the quencher
concentration, and Ksv is the Stern-Volmer quenching
constant which indicates the strength of interaction be-
tween albumin and a quencher molecule.
Hence, this equation was applied to determine Ksv
values by linear regression of a plot of F0/F against [Q].
The static quenching differs from dynamic quenching by
their dependence on temperature [16]. Dynamic quench-
ing depends upon diffusion, and higher temperatures
result in larger diffusion coefficients. As a result, the
Stern-Volmer quenching constants (Ksv) were expected
to increase with increasing temperature. In contrast, an
increased temperature is likely to result in decreasing
stability of complexes and thus a lower value of static
quenching constants [17]. The pattern of quenching of
BSA fluorescence by aceclofenac was determined by
measuring the value of Stern-Volmer quenching con-
stant (Ksv) values at the excitation wavelength of BSA
(280 nm) at two different temperatures (298 and 308 K).
Ksv values were calculated from the slope of the plot of F/
F0 versus the concentration of aceclofenac based on the
fluorescence data (Fig. 4) at the experimental conditions.
Figure 4 displays the Stern-Volmer plots of the quench-
ing of BSA fluorescence by aceclofenac at the excitation
Fig. 3 Fluorescence emission spectra of aceclofenac-BSA system at the excitation of a 280 nm at 298 K, b 293 nm at 298 K, and c 280 nm at
308 K. [Concentration of BSA = 0 μM; concentrations of aceclofenac from a to h: (a) 0, (b) 20, (c) 40, (d) 80, (e) 120, (f) 160, (g) 240, and (h) 320 μM]
Fig. 4 The Stern-Volmer plots for aceclofenac-BSA system at the
excitation wavelength of BSA at 280 nm at two different temperatures
(298 and 308 K)
Table 1 The Stern-Volmer quenching constant (Ksv) for
aceclofenac-BSA system at 280 nm at 298 and 308 K
temperatures
Temperature (K) Stern-Volmer quenching constant, Ksv (L mol
−1)
298 1.27 × 105
308 1.53 × 105
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wavelength of BSA (280 nm) at 298 K temperature. The
plots showed that within the experimental concentrations,
the results were in good agreement with the Stern-
Volmer equation. The plots were linear, and Stern-
Volmer quenching constants were obtained from the
slopes at two different temperatures. These are pre-
sented in Table 1. The Stern-Volmer quenching con-
stant decreased with increasing temperature for static
quenching while for dynamic quenching, the reverse
effect was observed [18]. It was seen from Table 1 that
the Ksv values increased by increasing temperature at
280 nm. So, it was found that dynamic quenching
occurred for BSA in the presence of aceclofenac by in-
creasing temperatures from 298 to 308 K.
Determination of thermodynamic parameters and nature
of binding forces
Fluorescence active substance and quencher can interact
to each other through different forces like hydrophobic
force, electrostatic interactions, van der Waals interac-
tions, and hydrogen bonds.
The thermodynamic parameters were calculated in
order to elucidate the interaction between the drug and
BSA, which was determined from the Van’t Hoff equa-
tion [19]:
ln Ka ¼ − ΔH=RTð Þ þ ΔS=Rð Þ
where ΔS is the entropy change, ΔH is the enthalpy
change, R is the universal gas constant, and Ka is the con-
stant which is analogous to the Stern-Volmer quenching
constants Ksv at the corresponding temperature.
The enthalpy change (ΔH) and the entropy change
(ΔS) can be determined from the slope and intercept of
the fitted curve of ln Ksv against 1/T, respectively (Fig. 5).
The free energy, ΔG, can be estimated from the follow-
ing relationship:
ΔG ¼ ΔHTΔS
Table 2 indicates that the enthalpy change (ΔH) and
the entropy change (ΔS) were positive and the free en-
ergy change (ΔG) was negative. This negative ΔG value
indicated that the binding of aceclofenac to BSA was
spontaneous. According to the views of Ross and Subra-
manian [20], the model of interaction between a drug
and biomolecule is frequently regarded as the evidence
for a hydrophobic interaction [21] because the water
molecules arranged in an orderly fashion around the
drug and protein establish a more random configuration.
So, it can be said that hydrophobic forces are playing a
major role in aceclofenac-BSA interaction at the wave-
length of 280 nm and 298 and 308 K temperatures
(Fig. 6).
Determination of binding constant and binding points
When aceclofenac binds independently to a set of equiva-
lent sites on BSA, the equilibrium between free and bound
aceclofenac is given by the following equation [22]:
Log F0=Fð Þ=F½  ¼ log Ka þ n log Q½ 
where Ka is the binding constant and n is the number of
binding sites per BSA molecule.
Table 2 Thermodynamic parameters for aceclofenac-BSA
system at 280 nm at two different temperatures (298 and 308 K)
Temperature (K) ΔH (kJ mol−1) ΔS (J mol−1) ΔG (kJ mol−1)
298 14.051 144.913 −25.52
308 −30.58
Fig. 6 Plot for binding constant and binding points for aceclofenac-BSA
at 280 nm at two different temperatures (298 and 308 K)
Fig. 5 The Van’t Hoff plot for aceclofenac-BSA system at 280 nm at
two different temperatures (298 and 308 K)
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The values of Ka and n are calculated from the values
of the intercept and slope of the plot of Log [(F0/F)/F]
versus log [Q].
Table 3 shows that the values of Ka for aceclofenac
and BSA decrease slightly with a rise in temperature
which may indicate that the complex of BSA and aceclo-
fenac is partly decomposed when the temperature rises.
The values of n were found to be ≈1 at both excitation
wavelengths of BSA at two different temperatures. The
molar ratio of the aceclofenac-BSA system at 280 nm
was 1:1 which indicated that 1 mol aceclofenac binds
with 1 mol of BSA.
Conclusions
The pharmacological activity of a drug is related to pro-
tein binding. Due to change in drug-protein interaction,
the activity of a drug increased or decreased. The study
indicated both tryptophan and tyrosine participated in the
interaction of BSA and aceclofenac. It was observed that
the fluorescence quenching of BSA occurred as a result of
dynamic quenching. Fluorescence quenching constants
were determined using the Stern-Volmer equation and
Van’t Hoff equation to provide a measure of the thermo-
dynamic parameters ΔG, ΔH, and ΔS. The binding process
for aceclofenac has been found spontaneous, exothermic,
and entropy driven as indicated by thermodynamic ana-
lysis, and hydrophobic forces are playing a major role in
the aceclofenac-BSA association. From this interaction
with albumin, we can get an idea about the consequences
of dose increment of this drug [23–25]. This study helps
us to design the aceclofenac as a predictive, preventive,
and personalized medicine.
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